' MAJOR FINDING' in Triple-Negative Breast Cancer'MAJOR FINDING' in Triple-Negative Breast Cancer
Triple-negative breast cancer is difficult to treat. A new study indicates that a common chemotherapy drug improves overall survival in this tumor type -- big news in cancer treatment.Medscape Medical News
British Journal of Cancer, Published online: 16 January 2020; doi:10.1038/s41416-019-0707-zSpecific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer
Neoadjuvant systemic therapy can facilitate breast conservation in certain women with stage II and III operable breast cancer. But compared to other countries, significantly fewer women in the United States make such a choice.Reuters Health Information
Conclusions Fatigue and exercise V˙O2 vary across a chemotherapy cycle. A chemotherapy-periodized exercise prescription that accommodates cyclical variations in fatigue may increase adherence to supervised exercise.
Conclusion: Certain cytokine gene variants may help detect susceptibiliy to cervical cancer, and predict response to chemoradiotherapy. PMID: 31935340 [PubMed - as supplied by publisher]
(University of Maryland School of Medicine) Researchers developed a new nanoparticle drug formulation that targets a specific receptor on cancer cells, and appears to be more effective than a standard nanoparticle therapy currently on the market to treat metastatic breast cancer. The study, published today in the journal Science Advances, found that the new 'DART' nanoparticles bypass healthy cells and tissues and bind to tumor cells, dispersing evenly throughout the tumor while releasing the chemotherapy drug paclitaxel.
This study provides data for consideration when discussing with patients the use of dietary supplements while undergoing chemotherapy.
DiscussionThe CARBON study is important as the results will be the first to assess radium-223 with chemotherapy in advanced breast cancer. If the results find acceptable rates of toxicity with a decrease in bone turnover markers, further work will be necessary in a phase II/III setting to assess the efficacy and clinical benefit.Trial registrationISRCTN,ISRCTN92755158, Registered on 17 February 2016.
AbstractPurpose of ReviewYoung women represent a minority of breast cancer patients for which fertility, family planning, and pregnancy represent unique vulnerabilities. This review intends to discuss recent published evidence regarding treatment-related infertility, fertility counseling, and preservation.Recent FindingsFertility concerns are common among young women with breast cancer and may negatively affect treatment decisions. Data is available to aid providers in approximating odds of post-treatment amenorrhea and infertility. Multiple fertility preservation techniques are available. While embryo preservation is most...
Cisplatin has been widely used in the treatment of a various types of cancers including triple-negative breast cancer (TNBC) by damaging DNA and inducing apoptosis. However, its anti-cancer effects are often limited due to chemo-resistance, which is one of the main reasons causing cancer relapse and metastasis. To overcome resistance, cisplatin is often used in combination with other drugs or molecules. Our study found that the targeted inhibition of miR-221/222 in MDA-MB-231 cells promoted cisplatin-induced cell apoptosis, and increased the cell sensitivity to cisplatin in vitro. Much higher expression levels of miR-221/2...
Conditions: Breast Cancer; Triple Negative Breast Cancer; HER2-positive Breast Cancer; Sentinel Lymph Node Intervention: Procedure: Omission of sentinel lymph node biopsy Sponsor: The Netherlands Cancer Institute Not yet recruiting